Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD -0.39%18 12-1 Month Momentum % is -66.40% as of Sep. 10, 2026. GuruFocus rates HKPD with a GF Score™ of 18/100. The stock has 4 warning signs investors should review. Among 123 Medical Distribution companies, Cellyan Biotechnology Co ranks worse than 95.12% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-10), Cellyan Biotechnology Co's 12-1 Month Momentum % is -66.40%.
The industry rank for Cellyan Biotechnology Co's 12-1 Month Momentum % or its related term are showing as below:
HKPD's 12-1 Month Momentum % is ranked worse than 95.12% of 123
companies
in the Medical Distribution industry
Industry Median: -11.1
vs HKPD: -66.40
Cellyan Biotechnology Co (NAS:HKPD) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Cellyan Biotechnology Co 12-1 Month Momentum % Related Terms
HKPD vs COSM, YI, MEDS: 12-1 Month Momentum % Comparison
For the Medical Distribution subindustry, Cellyan Biotechnology Co's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co 12-1 Month Momentum % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's 12-1 Month Momentum % falls into.
Cellyan Biotechnology Co (NAS:HKPD) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -66.40% mean?
Cellyan Biotechnology Co (HKPD) has a 12-1 Month Momentum % of -66.40% as of Sep. 10, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Cellyan Biotechnology Co and its competitors. According to the industry distribution chart, Cellyan Biotechnology Co ranks #117 out of 123 companies in the Medical Distribution industry, placing it in the top 95.1%.
Is Cellyan Biotechnology Co's 12-1 Month Momentum % too high?
Cellyan Biotechnology Co's current 12-1 Month Momentum % is -66.40%. Based on the distribution chart, Cellyan Biotechnology Co ranks #117 out of 123 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cellyan Biotechnology Co has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's 12-1 Month Momentum % compare to COSM and YI?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #117 out of 123 companies for 12-1 Month Momentum %. This places Cellyan Biotechnology Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Distribution company?
A good 12-1 Month Momentum % depends on the Medical Distribution industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Cellyan Biotechnology Co and its competitors. Cellyan Biotechnology Co's current 12-1 Month Momentum % is -66.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current 12-1 Month Momentum % of -66.40%. The current 12-1 Month Momentum % is -66.40%. Cellyan Biotechnology Co's overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current 12-1 Month Momentum % is -66.40% as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
18GF Score
Get the complete analysis for HKPD
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
